Meeting
2022 ASCO Annual Meeting
A cell-free RNA-based next-generation sequencing (NGS) assay for the detection of actionable gene fusions in patients with non–small cell lung cancer (NSCLC).
Presenter
Yukti Choudhury, PhD
Lucence Diagnostics
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3040)
DOI
10.1200/JCO.2022.40.16_suppl.3040
Abstract #
3040
Poster Bd #
32
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
Speaker: Joel W. Neal, MD, PhD
Speaker: Monica M. Bertagnolli, MD, FACS, FASCO
Speaker: Ulka N. Vaishampayan, MD
Videos & Slides
2021 ASCO Annual Meeting
Panel Question and Answer with Drs. Ansell, Gomez, and Griggs
Speaker: Panel Discussion